VRTX Logo

Vertex Pharmaceuticals Incorporated (VRTX) 

NASDAQ
Market Cap
$127.49B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
762 of 776
Rank in Industry
424 of 433

Largest Insider Buys in Sector

VRTX Stock Price History Chart

VRTX Stock Performance

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical …

Insider Activity of Vertex Pharmaceuticals Incorporated

Over the last 12 months, insiders at Vertex Pharmaceuticals Incorporated have bought $0 and sold $107.91M worth of Vertex Pharmaceuticals Incorporated stock.

On average, over the past 5 years, insiders at Vertex Pharmaceuticals Incorporated have bought $8.19M and sold $99.29M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $1.96M was made by Kewalramani Reshma (CEO & President) on 2021‑08‑19.

List of Insider Buy and Sell Transactions, Vertex Pharmaceuticals Incorporated

2024-10-02SaleEVP and Chief Legal Officer
999
0.0004%
$461.66$461,198+2.90%
2024-08-30SaleExecutive Chairman
3,784
0.0015%
$499.00$1.89M-4.52%
2024-08-30Saledirector
646
0.0003%
$500.00$323,000-4.52%
2024-08-08Saledirector
1,292
0.0005%
$466.29$602,447+2.17%
2024-08-07SaleEVP and CMO
2,280
0.0009%
$476.75$1.09M+2.17%
2024-08-01Saledirector
5,295
0.0021%
$508.00$2.69M-5.89%
2024-07-30SaleCEO & President
15,202
0.0059%
$505.00$7.68M+0.15%
2024-07-24SaleEVP and CMO
2,280
0.0009%
$488.46$1.11M+0.78%
2024-07-22SaleCEO & President
15,202
0.0059%
$497.00$7.56M-3.83%
2024-07-10SaleEVP and CMO
2,280
0.0009%
$487.34$1.11M0.00%
2024-06-26SaleEVP and CMO
2,280
0.0009%
$471.72$1.08M+0.91%
2024-06-12SaleEVP and CMO
2,280
0.0009%
$478.00$1.09M+0.24%
2024-06-12SaleEVP, Chief Technical Ops. Off.
7,288
0.0028%
$478.00$3.48M+0.24%
2024-06-03SaleEVP, Chief Reg. & Quality Off.
2,175
0.0008%
$460.00$1M+1.60%
2024-06-03SaleEVP & Chief Financial Officer
3,250
0.0012%
$460.00$1.5M+1.60%
2024-05-31SaleEVP, Chief Reg. & Quality Off.
2,250
0.0009%
$445.00$1M+4.95%
2024-05-30SaleEVP, Chief Reg. & Quality Off.
2,350
0.0009%
$439.11$1.03M+7.75%
2024-05-29SaleEVP and CMO
2,280
0.0009%
$445.56$1.02M+8.11%
2024-05-28SaleEVP & Chief Financial Officer
3,250
0.0013%
$454.79$1.48M+6.55%
2024-05-24SaleCEO & President
1,565
0.0006%
$457.00$715,205+4.20%

Insider Historical Profitability

18%
Kewalramani ReshmaCEO & President
90970
0.0352%
$493.96126+20.8%
Sachdev AmitEVP Chief Patient & Ext Af Off
55325
0.0214%
$493.961103+5.21%
SACHS BRUCE Idirector
40000
0.0155%
$493.96733+20.85%
LEIDEN JEFFREY MExecutive Chairman
9994
0.0039%
$493.96252<0.0001%
Vertex Pharmaceuticals (Europe) Ltd10 percent owner
5380940
2.0848%
$493.9640+14.31%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Capital World Investors$10.69B9.9125.57M+17.25%+$1.57B1.77
The Vanguard Group$9.48B8.7922.68M+1.77%+$164.84M0.18
BlackRock$9.18B8.5121.96M+0.36%+$33.23M0.2
State Street$5.02B4.6512.01M-0.64%-$32.33M0.21
Fidelity Investments$4.46B4.1410.67M-17.77%-$963.93M0.3
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.